Nebivolol Arrow (Nebivolol)

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

• Hypertension: reduction of elevated blood pressure in adult patients.
• Heart failure: improvement of symptoms and reduction of hospitalization risk in patients with chronic heart failure.
• Left ventricular dysfunction: support of cardiac output in patients with reduced ejection fraction.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility. Concurrently, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release, which causes vasodilation and lowers peripheral vascular resistance, contributing to overall blood pressure reduction.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Dizziness: sensation of light‑headedness, especially when standing quickly.
• Fatigue: general tiredness or lack of energy.
• Bradycardia: slower than normal heart rate.
• Nausea: feeling of stomach upset or urge to vomit.
• Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Symptomatic hypotension: significant drop in blood pressure causing faintness.
• Heart block: impairment of electrical conduction in the heart.
• Bronchospasm: narrowing of airways, particularly in patients with asthma.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Liver enzyme elevation: abnormal liver function tests.

Before initiating Nebivolol therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Blood pressure monitoring: regularly assess to ensure therapeutic control.
• Cardiac function assessment: evaluate heart rate and ECG for bradyarrhythmias.
• Hepatic impairment: adjust use in patients with moderate to severe liver disease.
• Concomitant beta‑blockers: avoid combining with other beta‑blocking agents without specialist guidance.
• Abrupt discontinuation: taper gradually to prevent rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Other beta‑blockers: additive negative chronotropic effects may cause severe bradycardia.
• Calcium‑channel blockers (verapamil, diltiazem): can potentiate AV‑node conduction delay.
• Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: may enhance antihypertensive effect, requiring blood pressure monitoring.

• Diuretics: combined use can lead to excessive blood pressure reduction.
• NSAIDs: may attenuate antihypertensive response.
• Antidiabetic agents: nebivolol may mask hypoglycemia symptoms; monitor glucose levels.